Clinical characteristics of connective tissue disease-Associated interstitial lung disease in 1,044 Chinese patients

Chest

Volumn 149, Issue 1, 2016, Pages 201-208

  Hu, Yang ^a   Wang, Liu Sheng ^a   Wei, Ya Ru ^a   Du, Shan Shan ^a   Du, Yu Kui ^a   He, Xian ^a   Li, Nan ^a   Zhou, Ying ^a   Li, Qiu Hong ^a   Su, Yi Liang ^a   Zhang, Fen ^a   Shen, Li ^a   Weng, Dong ^a   Brown, Kevin K ^b   Li, Hui Ping ^a  

^a TONGJI UNIVERSITY   (China)

^b DEPARTMENT OF MEDICINE   (United States)

Author keywords

Interstitial Lung Disease; Pulmonary Epidemiology; Pulmonary Fibrosis

Indexed keywords

ANTIFIBROTIC AGENT; ANTIRHEUMATIC AGENT; AUTOANTIBODY; GLUCOCORTICOID;

ADULT; ANTIBODY DETECTION; ARTICLE; CHINESE; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DISEASE ASSOCIATION; EXTRAPULMONARY SYMPTOM; FEMALE; FIBROSING ALVEOLITIS; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; LUNG BIOPSY; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT INFORMATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY SYMPTOM; RETROSPECTIVE STUDY; SYMPTOM; AGED; CHINA; CONNECTIVE TISSUE DISEASES; HOSPITALIZATION; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; MORTALITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; CHINA; CONNECTIVE TISSUE DISEASES; FEMALE; HOSPITALIZATION; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84954130722     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.15-1145     Document Type: Article

References (23)

1. Fischer A, Antoniou K, Brown KK, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015; 46(4):976-987.
2. Karakatsani A, Papakosta D, Rapti A, et al. Epidemiology of interstitial lung diseases in Greece. Respir Med. 2009; 103(8):1122-1129.
3. Alhamad EH. Interstitial lung diseases in Saudi Arabia: a single-center study. Ann Thorac Med. 2013;8:33-37.
4. Castelino FV, Varga J. Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res Ther. 2010;12(4):213.
5. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013; 188(6):733-748.
6. Goldman L, Schafer AI. Goldmans Cecil Medicine. 24th ed. Amsterdam, Netherlands: Elsevier Medicine; 2011: 556-560
7. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-324.
8. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23(5): 581-590.
9. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344-347.
10. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271-1277.
11. Vitali C, Bombardieri S, Moutsopoulos HM, et al. Assessment of the European classification criteria for Sjgrens syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjgrens Syndrome. Ann Rheum Dis. 1996;55(2):116-121.
12. Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease-An apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972;52(2):148-159.
13. Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet. 2012;380(842): 689-698.
14. Kinder BW, Collard HR, Koth L, et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med. 2007;176(7): 691-697.
15. Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171(9):1040-1047.
16. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079-1087.
17. Velez MI, Nambiar AM. Combination pirfenidone and inhaled N-Acetylcysteine therapy for IPF: does it take these two to tango? Respirology. 2015;20(3):359-360.
18. Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;186(1): 88-95.
19. Cottin V. Interstitial lung disease: are we missing formes frustes of connective tissue disease? Eur Respir J. 2006;28(5): 893-896.
20. Fischer A, West SG, Swigris JJ, et al. Connective tissue disease-Associated interstitial lung disease: a call for clarification. Chest. 2010;138(2):251-256.
21. Antoniou KM, Margaritopoulos G, Economidou F, et al. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J. 2009;33(4): 882-896.
22. Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med. 2012;185(11):1147-1153.
23. Su R, Bennett M, Jacobs S, et al. An analysis of connective tissue diseaseassociated interstitial lung disease at a US Tertiary Care Center: better survival in patients with systemic sclerosis. J Rheumatol. 2011;38(4):693-701.